Results 231 to 240 of about 14,877 (300)

Coronary stenting and use of abciximab

The Lancet, 1998
1claim that “a new standard for prevention of major adverse ischaemic outcomes with percutaneous coronary revascularisation procedures has emerged”, and caution that “the cost effectiveness of abciximab needs to be fully assessed”. A critical issue that they do not address is the outcome of patients requiring emergency coronary-artery bypass graft ...
Wolfgang Mohl, Markus Menges, Hermann Schieffer, Benno Hennen, Martin Zeitz   +4 more
  +8 more sources

Antithrombotic effects of Abciximab

The American Journal of Cardiology, 2000
The observation that platelet-platelet interaction and thrombosis are ultimately regulated by the glycoprotein (GP) IIb/IIIa receptor complex, triggered the development of agents capable of interfering with this platelet receptor complex. Several large clinical trials have demonstrated the effectiveness of this class of agents.
George Dangas, Valentin Fuster, John T. Fallon, Richard Hayes, Samin K. Sharma, Jonathan D. Marmur, Barry S. Coller, Lina Badimon, Juan J. Badimon, James H. Chesebro   +9 more
openaire   +3 more sources

Intracoronary tenecteplase versus abciximab as adjunctive treatment during primary percutaneous coronary intervention in patients with anterior myocardial infarction.

EuroIntervention, 2019
AIMS We sought to compare the effects of intracoronary administration of a fibrinolytic drug (tenecteplase) to those of a glycoprotein IIb/IIIa inhibitor (abciximab) in patients with ST-elevation myocardial infarction (STEMI) undergoing primary ...
Francisco J. Morales-Ponce, Francisco J. Lozano-Cid, P. Martínez-Romero, Pablo J. González-Pérez, J. Sánchez-Brotons, I. Diaz-Torres, J. C. Rodríguez-Yáñez, Pilar Caro-Mateo, A. Serrador-Frutos   +8 more
semanticscholar   +1 more source

Rationale for intracoronary administration of abciximab

Journal of Thrombosis and Thrombolysis, 2006
The present review aims to describe the pharmacological aspects as well as the available clinical data supporting the choice of intracoronary route of administration for abciximab, an antiplatelet drug used in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI).
Romagnoli E., Burzotta F., Trani C., Biondi-Zoccai G. G. L., Giannico F., Crea F.   +5 more
openaire   +5 more sources

Use of abciximab in interventional cardiology

American Heart Journal, 1998
The advent of platelet membrane glycoprotein (GP) IIb/IIIa inhibitors has changed the landscape of interventional cardiology. Given the commercial availability of abciximab and expected regulatory approvals for other receptor blockers, defining appropriate use of these agents in the interventional setting is mandated.
Dietrich C. Gulba, Alec Vahanian, Ben A. van Hout, Håkan Emanuelsson, Amadeo Betriu, Sheldon Goldberg, Nicolas Af Chronos   +6 more
openaire   +4 more sources

Half bolus dose of intravenous abciximab is safe and effective in the setting of acute stroke endovascular treatment

Journal of NeuroInterventional Surgery, 2018
Background A stent is often necessary for the treatment of stroke. In such cases,it is essential for the patient to have antiplatelet therapy.
F. Delgado, R. Oteros, E. Jiménez-Gómez, I. Bravo Rey, M. D. Bautista, R. Valverde Moyano   +5 more
semanticscholar   +1 more source

Intracoronary versus intravenous bolus abciximab during primary percutaneous coronary intervention in patients with acute ST-elevation myocardial infarction: a randomised trial

Lancet, The, 2012
Holger Thiele, Jochen Wöhrle, Ingo Eitel   +2 more
exaly   +2 more sources

Intracoronary or intravenous abciximab after aspiration thrombectomy in patients with STEMI undergoing primary percutaneous coronary intervention.

Cardiovascular Journal of Africa, 2019
OBJECTIVE To test whether aspiration thrombectomy with intracoronary (IC) instead of intravenous (IV) administration of abciximab could reduce the no-reflow phenomenon in patients undergoing primary percutaneous intervention (PCI) for ST-elevation ...
A. Bedjaoui, Karima Allal, M. S. Lounes, Chamseddine Belhadi, Abdelmoumen Mekarnia, Saber Sediki, M. Kara, A. Azaza, J. Monsuez, S. Benkhedda   +9 more
semanticscholar   +1 more source

Possible anaphylactic reaction to abciximab

Catheterization and Cardiovascular Interventions, 1999
We report a patient who experienced a severe anaphylactic reaction during coronary artery stenting. Subsequent to administration of a weight-adjusted dose of abciximab, the patient developed profound hypotension and severe, acute airway obstruction. The reaction was successfully reversed with a 16-hr infusion of epinephrine, steroids, and an H1 blocker.
Joseph A. Guzzo, Timothy C. Nichols
openaire   +3 more sources

Abciximab and Heparin versus Bivalirudin for Non–ST-Elevation Myocardial Infarction

New England Journal of Medicine, 2011
Adnan Kastrati, Stefanie Schulz, Steffen Massberg   +2 more
exaly   +2 more sources